Drugs / TORL-4-500
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06005740 | Dec 2023 → Oct 2025 overdue | hepatocellular carcinoma | TORL Biotherapeutics, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TORL-4-500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005740 ↗ |
| Route | Intravenous | “TORL-4-500 iv once every 3 weeks” NCT06005740 ↗ |